Pretreatment evaluation of chronic hepatitis C: Risks, benefits, and costs

JAMA

Volumn 280, Issue 24, 1998, Pages 2088-2093

  Wong, John B ^a,c   Bennett, William G ^a   Koff, Raymond S ^b   Pauker, Stephen G ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b METROWEST MEDICAL CENTER   (United States)

^c TUFTS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON;

ARTICLE; CHRONIC DISEASE; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; HEPATITIS C; HUMAN; HUMAN CELL; INFECTION RISK; LIFE EXPECTANCY; LIVER BIOPSY; OUTCOMES RESEARCH; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; VIRUS LOAD;

EID: 0032583497     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.280.24.2088     Document Type: Article

References (16)

1. Deaths and hospitalizations from chronic liver disease and cirrhosis - United States, 1980-1989. MMWR Morb Mortal Wkly Rep. 1993;41:969-973.
2. Fried MW, Hoofnagle JH. Therapy of hepatitis C. Semin Liver Dis. 1995;15:82-91.
3. Bennett WG, Inoue Y, Beck JR, Wong JB, Pauker SG, Davis GL. Estimates of the cost-effectiveness of a single course of Interferon alfa-2b in patients with histologically mild chronic hepatitis C. Ann Intern Med. 1997;127:855-865.
4. Kim WR, Poterucha JJ, Hermans JE, et al. Cost-effectiveness of 6 and 12 months of interferon-alfa therapy for chronic hepatitis C. Ann Intern Med. 1997;127:866-874.
5. McQuillan G, Alter M, Moyer L, Lambert S, Margolis H. A population-based serologic study of hepatitis C in the United States. Am J Epidemiol. 1996;143(suppl):S32.
6. Beck JR, Pauker SG. The Markov Process in medical prognosis. Med Decis Making. 1983;3:419-458.
7. Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med Decis Making. 1993;13:322-338.
8. Zein NN, Persing DH. Hepatitis C genotypes: current trends and future implications. Mayo Clin Proc. 1996;71:458-462.
9. Martinot-Peignoux M, Marcellin P, Pouteau M, et al. Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon alfa therapy in chronic hepatitis C. Hepatology. 1995;22:1050-1056.
10. Nousbaum JB, Pol S, Nalpas B, Landais P, Berthelot P, Brechot C. Hepatitis C virus type 1b (II) infection in France and Italy: Collaborative Study Group. Ann Intern Med. 1995;122:161-168.
11. Saracco G, Rosina F, Abate ML, et al. Long-term follow-up of patients with chronic hepatitis C treated with different doses of interferon alfa-2b. Hepatology. 1993;18:1300-1305.
12. Qu D, Li J, Vitvitski L, et al. Hepatitis C virus genotypes in France: comparison of clinical features of patients infected with HCV type I and type II. J Hepatol. 1994;21:70-75.
13. Younossi ZM, McHutchison JG. Interferon treatment of chronic HCV infection: an economic analysis of different strategies. Gastroenterology. 1996;110(suppl):A47.
14. Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ. Classification of chronic hepatitis: diagnosis, grading, and staging. Hepatology. 1994;19:1513-1520.
15. Marcellin P, Pouteau M, Benhaou JP. Hepatitis C virus infection, alpha interferon therapy and thyroid dysfunction. J Hepatol. 1995;22:364-369.
16. Chemello L, Bonetti P, Cavalletto L, et al. Randomized trial comparing three different regimens of alfa-2a interferon in chronic hepatitis C. Hepatology. 1995;22:700-706.